Doxorubicin‐eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma

@article{Huang2014DoxorubicinelutingBV,
  title={Doxorubicin‐eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma},
  author={Kai-jun Huang and Qian Zhou and Rong Wang and Donghui Cheng and Yin Ma},
  journal={Journal of Gastroenterology and Hepatology},
  year={2014},
  volume={29}
}
Doxorubicin‐eluting bead transarterial chemoembolization (DEB‐TACE) is a novel locoregional treatment for unresectable hepatocellular carcinoma (HCC). However, to date, the benefits of DEB‐TACE versus conventional transarterial chemoembolization (TACE) remain unclear. This meta‐analysis was conducted to evaluate the efficacy and safety of the two treatments for patients with unresectable HCC. 
View on Wiley
or.nsfc.gov.cn
94 Citations
Highly Influential Citations
2
Background Citations
19
Methods Citations
4
Results Citations
6

94 Citations

Citation Type

Citation Type

Systematic review comparing the safety and efficacy of conventional and drug‐eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma
  • Z. Xie, Xiao-bo Wang, +9 authors J. Zhong
  • Medicine
    Hepatology research : the official journal of the Japan Society of Hepatology
  • 2015
TLDR
A current, comprehensive picture is gained of how DEB‐TACE compares with cTACE to gain a current, complete picture of how the technique based on drug‐eluting beads compares with conventional transarterial chemoembolization.
Conventional versus drug‐eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size
This study aims to evaluate clinical outcomes of patients with hepatocellular carcinoma who underwent transarterial chemoembolization (TACE) using drug‐eluting beads (DEB).
Preservation of quality of life with doxorubicin drug‐eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study
The study aims to determine the effects of doxorubicin drug‐eluting bead transarterial chemoembolization (DEB‐TACE) therapies on health‐related quality of life (HRQOL) in patients with unresectable…
Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma
TLDR
The clinical efficacy and safety of DEB-TACE for patients with intermediate or advanced stage HCC in comparison with cTACE are summarized.
Update on Transarterial Chemoembolization with Drug-Eluting Microspheres for Hepatocellular Carcinoma
TLDR
A review summarizes the recent advances in the use of DEM-TACE to treat HCC and ensures the delivery of high concentrations of chemotherapeutic agents to tumors, without increasing systemic concentrations, and promote tumor ischemia and necrosis.
Huge Hepatocellular Carcinoma Treated with Radical Hepatectomy after Drug-eluting Bead Transarterial Chemoembolization
TLDR
As most intrahepatic metastases disappeared following DEB-TACE, the patient was able to undergo radical hepatectomy, and has maintained a complete response.
Efficacy and safety of cTACE versus DEB‐TACE in patients with hepatocellular carcinoma: a meta‐analysis
TLDR
This meta‐analysis aimed to update and re‐evaluate the efficacy and safety of cTACE compared with those of DEB‐TACE in patients with hepatocellular carcinoma (HCC).
Conventional Transarterial Chemoembolization Versus Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
TLDR
Treatment with DEB-T ACE appears to be non-inferior compared to conventional C-TACE and associated with a better objective response and disease control with fewer severe complications and all-cause mortality.
Short‐term efficacy, safety, and cost‐effectiveness of transarterial chemoembolization with drug‐eluting beads versus synchronous radiochemotherapy for cervical cancer
  • Jingjing Song, Weiqian Chen, +7 authors J. Ji
  • Medicine
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • 2019
To investigate the short‐term efficacy and safety of transarterial chemoembolization with drug‐eluting beads (DEB‐TACE) versus synchronous radiochemotherapy among women with cervical cancer.
A Lethal Complication after Transarterial Chemoembolization with Drug-Eluting Beads for Hepatocellular Carcinoma
TLDR
It is speculated that DEB-TACE has a prolonged effect on the tumor and the surrounding liver, resulting in progressive enlargement of the necrotic area and death in patients affected by multifocal HCC.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 53 REFERENCES
Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC)
TLDR
This study explores long‐term survival benefits of chemoembolization with doxorubicin drug eluting beads for unresectable hepatocellular carcinoma and suggests that treatment with DEB may provide safer and more effective short‐term outcomes.
Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma.
Prospective Randomized Comparison of Chemoembolization with Doxorubicin-Eluting Beads and Bland Embolization with BeadBlock for Hepatocellular Carcinoma
TLDR
Evaluating the added role of a chemotherapeutic in transarterial chemoembolization of intermediate-stage hepatocellular carcinoma found DEB-TACE presents a better local response, fewer recurrences, and a longer TTP than bland embolization with BeadBlock, however, survival benefit and bland embols with smaller particles must be addressed in future papers to better assess the clinical value.
Transarterial Chemoembolization of Unresectable Hepatocellular Carcinoma with Drug Eluting Beads: Results of an Open-Label Study of 62 Patients
TLDR
It is concluded that hemoembolization using doxorubicin-loaded DC Beads is a safe and effective treatment of HCC as demonstrated by the low complication rate, increased tumor response, and sustained reduction of α-fetoprotein levels.
Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma.
Chemoembolization of unresectable hepatocellular carcinoma: Decreased toxicity with slow-release doxorubicin‑eluting beads compared with lipiodol.
TLDR
DDEB-TACE with doxorubicin-loaded DC Beads, a safe and reliable treatment for HCC, leads to decreased toxicity compared to TACE, and this phase II study shows a statistically significant decrease in liver enzymes and lactate dehydrogenase.
Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE)
TLDR
Associated with a similar safety profile and an at least comparable tumour response, the DEB-TACE is a method of treatment for HCC that has the potential to improve mean survival compared to cTACE with Cisplatin/Lipiodol.
[Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].
Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study
TLDR
TACE with DC Bead and doxorubicin is safe and effective in the treatment of HCC and offers a benefit to patients with more advanced disease.
[Economic impact of transarterial chemoembolization with drug eluting beads in the treatment of hepatocellular carcinoma].
TLDR
A first TACE using drug eluting beads, valued by the official tariffs from the new French Diagnosis Related Group prospective payment system, is significantly (p  =  0.006) less expensive than a first conventional TACE.
...
1
2
3
4
5
...